Table 4.

Analysis of risk factors for weak immune response (<500 SARS-CoV-2 anti-RBD) of pregnant women based on micronutrient supplementation during pregnancy.

	No Supplementation (OR–95% CI)	p-Value	Magnesium Supplementation (OR–95% CI)	p-Value
Age
<25 ^	0.91 (0.72–1.10)	0.572	0.84 (0.60–1.13)	0.662
25–34	0.99 (0.76–1.24)	0.384	0.92 (0.84–1.27)	0.513
>34	1.12 (1.01–1.38)	0.047	1.04 (0.82–1.21)	0.296
Obesity
No ^	0.94 (0.63–1.48)	0.316	0.88 (0.36–1.44)	0.581
Yes	1.56 (1.28–2.34)	0.011	1.42 (1.05–1.93)	0.040
Duration of supplementation
<9 months	1.18 (0.78–1.69)	0.427	1.04 (0.75–1.28)	0.338
≥9 months ^	1.01 (0.83–1.26)	0.290	0.92 (0.81–1.05)	0.194
Vitamin D supplementation
No	1.17 (0.91–1.32)	0.522	1.01 (0.88–1.39)	0.194
Yes ^	0.85 (0.36–1.16)	0.314	0.76 (0.62–0.92)	0.086
COVID-19 severity
Mild ^	1.33 (1.02–0.78)	0.071	1.24 (1.09–1.76)	0.142
Moderate	1.13 (0.93–1.42)	0.461	1.05 (0.83–1.41)	0.510
Severe	0.86 (0.72–0.98)	0.283	0.82 (0.69–1.05)	0.308
Days since COVID-19 clearance
<90 days ^	1.10 (0.99–0.48)	0.308	0.99 (0.72–0.98)	0.416
≥90 days	1.62 (1.24–2.15)	0.001	1.27 (1.04–1.82)	0.008
Magnesium dose
<450 mg ^	-	-	1.25 (1.08–1.66)	0.003
≥450 mg	-	-	0.98 (0.63–1.17)	0.372

^{^} Reference category.